Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04249102
Other study ID # CGM2020/1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 12, 2020
Est. completion date February 2022

Study information

Verified date January 2020
Source Queen Fabiola Children's University Hospital
Contact Anissa Messaaoui, MD
Phone +32.2.477.33.84
Email anissa.messaaoui@huderf.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Impaired hypoglycemia awareness, a significant problem for children with type 1 diabetes, is defined as neurogenic symptom response before autonomic response to hypoglycemia. Avoiding hypoglycemia appears to restore hypoglycemia awareness.

Investigators have previously demonstrated in a retrospective study that Flash Glucose Monitoring system decreased the risk of severe hypoglycemia in type 1 diabetic children and adolescents, even though Flash Glucose Monitoring system, unlike Continuous Glucose Monitoring system, does not provide glucose alerts.

Continuous Glucose Monitoring system, by providing real-time data with alarms, could benefit to subjects still experiencing severe hypoglycemia with Flash Glucose Monitoring system. Besides, in adults, Continuous Glucose Monitoring system reduced more effectively impaired hypoglycemia awareness compared to Flash Glucose Monitoring system.

In that context, investigators would like to assess the impact of Continuous Glucose Monitoring system instead of Flash Glucose Monitoring system on hypoglycemia in children and adolescents with type 1 diabetes.


Description:

All subjects will start with a 7 days run-in phase using their current Flash Glucose Monitoring System associated with a blind Continuous Glucose Monitoring system (Envision, Medtronic).

After one week, subjects randomized in the the interventional group will be provided with the Continuous Glucose Monitoring (Guardian Connect, Medtronic) and trained by dedicated diabetes educators for Continuous Glucose Monitoring usage including insertion of the sensor, calibration of the device twice daily and interpretation of the data. Subjects will use the sensors according to the license.

For both groups, insulin doses decisions are made by the participant according the received education.

After one week, all subjects will be contacted by phone focusing on the use of the technology. The treatment period is 8 weeks. The last week of the treatment period, subjects will use the blind Continuous Glucose Monitoring system (Envision, Medtronic) in addition to their allocated Glucose Monitoring system.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date February 2022
Est. primary completion date February 2022
Accepts healthy volunteers No
Gender All
Age group 4 Years to 20 Years
Eligibility Inclusion Criteria:

- Male and female aged from 4 to 20 years

- Subjects with onset of diabetes before 16 years of age

- Diabetes duration of more than 1 year

- Subject currently using Flash Glucose Monitoring system in daily practice

Exclusion Criteria:

- Subject with mental disability

- Previous use of Continuous Glucose Monitoring system

- Subject currently participating to another clinical study

Study Design


Intervention

Device:
Guardian Connect, Medtronic
Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
Abbott Diabetes Care
Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.

Locations

Country Name City State
Belgium Hôpital Universitaire Des Enfants Reine Fabiola Brussels

Sponsors (1)

Lead Sponsor Collaborator
Queen Fabiola Children's University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the change in baseline hypoglycemia after 8-week Continuous Glucose Monitoring system use % of Time-Below-Range (i.e. < 70 mg/dl) At Baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in severe hypoglycemia frequency in patients using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. Number of severe hypoglycaemia (i.e. hypoglycemic event leading leading to loss of consciousness) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in HbA1c in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. HbA1c value in % At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in glycemic variability in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent in the target range (70 - 180 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in glycemic variability in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent above the target range (> 180 mg/dl and > 250 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in glycemic variability in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent below the target range (< 70 mg/dl and < 54 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in glycemic variability in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. Coefficient of variation (SD/Mean) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in glycemic variability in patients monitored with Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. low blood glucose index At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in the quality of life of patients using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. EQ-5D-3L Questionnaire At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in severe hypoglycemia frequency in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. Number of severe hypoglycaemia (i.e. hypoglycemic event leading leading to loss of consciousness) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in HbA1c in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. HbA1c value in % At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To assess the change in glycemic variability in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent in the target range (70 - 180 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To assess the change in glycemic variability in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent above the target range (> 180 mg/dl and > 250 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To assess the change in glycemic variability in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. % of time spent below the target range (< 70 mg/dl and < 54 mg/dl) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To assess the change in glycemic variability in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. Coefficient of variation (SD/Mean) At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To assess the change in glycemic variability in patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. low blood glucose index At baseline and after 8 weeks of Continuous Glucose Monitoring system use
Secondary To evaluate the change in the quality of life of patients with and without impaired hypoglycemia awareness using Continuous Glucose Monitoring system in comparison to Flash Glucose Monitoring system. EQ-5D-3L Questionnaire At baseline and after 8 weeks of Continuous Glucose Monitoring system use
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4